BIND Therapeutics has entered into a research agreement with Roche to discover nanomedicines for the treatment of diseases in therapeutic areas outside of oncology. The collaboration will focus on combining BIND’s Accurin technology with Roche’s therapeutic payloads and targeting ligands.
“By combining BIND’s Medicinal Nanoengineering® platform with Roche’s deep expertise in disease areas with high unmet medical need, this agreement further validates the wide-ranging potential for our technology and facilitates extending our platform into new therapeutic areas,” said Scott Minick, CEO of BIND Therapeutics.
In the past, BIND has announced collaborations with Amgen, Pfizer, and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines. Last year, BIND entered into a global collaboration agreement with Amgen to develop and commercialize a kinase inhibitor nanomedicine for treating a range of solid tumors based on BIND's platform and Amgen's undisclosed kinase inhibitor. As part of the agreement, Amgen has to exercise its option to select a novel Accurin candidate for further development by July 2014 to allow for completion of the research plan.